Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Yet it didnt work
Garza et al
**The competitor prices shown are compiled from monthly research using publicly available information from competitor websites
The company recently achieved two major milestones, including the successful completion of a Phase II clinical trial in 32 patients aged 12 years and older, which demonstrated a clinically meaningful reduction in hyperphagia along with a favourable safety and tolerability profile
Patients should never use external heat sources or microwaves to warm the medication, as this may damage the medication
Although ponatinib is an FDA-approved TKI that directly targets T315I-Bcr-Abl leukemia, its association with cardiovascular toxicity is a significant concern in clinical therapy
US$ 24.98
US$ 22.91
US$ 27.30
US$ 20.75
US$ 20.22
